Rheumatoid Arthritis MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis
Conditions
Interventions
Product Name: LY3009104
Product Code: LY3009104
Pharmaceutical Form: Capsule*
INN or Proposed INN: Not available
CAS Number: 1187595-84-1
Current Sponsor code: LY3009104 phosphate
Other descriptive na
Sponsors
Eli Lilly and Company
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [1] Ambulatory males or females between the ages of 18 and 75 years, inclusive. [1a] Male patients: Agree to use a reliable method of birth control during the study. [1b] Female patients: Females must not be pregnant, breastfeeding, or at risk to become pregnant during study participation. Female patients of childbearing potential, must test negative for pregnancy at the time of enrollment and agree to use a reliable method of birth control or remain abstinent during the study or for at least 30 days following the last dose of study drug, whichever is longer, or, must be a female of non-childbearing potential, defined as: - women who have had surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation), - women =60 years of age, or - women =40 and 1.2 times upper limit of normal (ULN) or Erythrocyte Sedimentation Rate (ESR) > upper limit of normal (28 mm/hr). The CRP and ESR may be repeated once during the screening period at the discretion of the investigator, and the repeat results may be accepted for study eligibility purposes. [8] Clinical laboratory test results within normal reference range for the central laboratory. (Note: This inclusion criterion only applies to clinical laboratory tests not specifically cited in any exclusion criteria below.) [9] Venous access sufficient to allow blood sampling as per the protocol. [10] Are reliable and willing to be available for the duration of the study and are willing to follow study procedures. [11] Are able to read, understand, and give written informed consent approved by Lilly or its designee and the ethical review board (ERB) governing the site. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: [1] Have received any parenteral corticosteroid administered by intra-articular, intramuscular, or IV injection within 6 weeks prior to baseline. [2] Have received either oral corticosteroids at average daily doses of >10 mg/day of prednisone (or equivalent) or used variable doses of oral corticosteroids within 6 weeks prior to baseline. [3] Use of NSAIDs for less than 4 weeks prior to baseline. [4] Have received any prior biologic DMARD therapy (such as TNFa, IL-1, IL-6, T-cell or B-cell targeted therapies). [5] Have previously completed or withdrawn from this study or any other study investigating LY3009104. [6] Received prior treatment with an oral JAK inhibitor. [7] Use of DMARDs other than stable treatment of MTX, hydroxychloroquine (up to 400 mg/day), and/or sulfasalazine (up to 3000 mg/day) in the 8 weeks prior to baseline. [8] Use of leflunomide in the 12 weeks prior to baseline (or a minimum of 4 weeks prior to baseline will be required if the standard 11 days of chlolestyramine is used to washout leflunomide). [9] Have active fibromyalgia that would make it difficult to appropriately assess RA activity for the purposes of this study or have a diagnosis of any systemic inflammatory condition other than RA. Patients with secondary Sjogren's syndrome with RA are not excluded. [10] Have evidence of active vasculitis. [11] Have a diagnosis of Felty’s syndrome. [12] Had surgical treatment of a joint that is to be assessed in the study within 2 months of study baseline or will require such during the study. [13] An abnormality in the 12-lead ECG that in the opinion of the investigator increases the risk of participating in the study. [14] Uncontrolled arterial hypertension characterized by a systolic BP >160 mmHg or diastolic BP >100 mmHg. [15] Have had lymphoma, leukemia, or any malignancy within the past 5 years, except for cervical carcinoma in situ that has been resected with no evidence of recurrence or metastatic disease, or basal cell or squamous epithelial skin cancers that have been completely resected with no evidence of recurrence for at least 3 years. [16] History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders that in the opinion of the investigator could constitute a risk or of interfere with the interpretation of data. [17] Evidence of significant active neuropsychiatric disease, in the opinion of the investigator. [18] Have a current or recent (<30 days prior to screening) viral, bacterial, fungal, or parasitic infection. [19] Had a serious infection or atypical mycobacterial infection within 6 months prior to screening. [20] Had symptomatic herpes zoster or herpes simplex infection within 90 days prior to baseline. [21] History of disseminated/complicated herpes zoster. [22] Evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies. [23] Have evidence of active or test positive for hepatitis C virus (HCV). [24] Evidence of active hepatitis B (positive for hepatitis B surface antigen [HBsAg+]) OR are positive for hepatitis B core antibody and negative for hepatitis B surface antibody (HBcAb+, HBsAb-). [25] Evidence of active or latent tuberculosis (TB) as documented by a positive purified protein derivative (PPD) test (=5 mm in duration between approximately 2 and 3 days after application. [26] Exposed to a live vaccine within 12 weeks prior to baseline or expected to need/receive a live vaccine (incl
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the efficacy of LY3009104 as assessed by the aggregate proportion of patients in the 4 mg and 8 mg dose groups who achieve an ACR20 response compared to placebo over 12 weeks in patients with active RA despite ongoing MTX therapy.;Secondary Objective: 1 - To characterize the dose-response relationship of LY3009104 on ACR (20/50/N) response rates over 12 weeks and to evaluate model-predicted responses for each dose versus placebo to identify one or more efficacious doses. 2 - To evaluate the efficacy of each dose of LY3009104 compared to placebo over 12 weeks. 3 - To evaluate the relative efficacy of each dose of LY3009104 over 24 weeks. 4 - To evaluate the safety and tolerability of LY3009104 compared to placebo. 5 - To evaluate the efficacy of twice-daily dosing of 2 mg of LY3009104 as compared to once-daily dosing of 4 mg of LY3009104. 6 - To evaluate the safety of twice-daily dosing of 2 mg of LY3009104 as compared to once daily dosing of 4 mg of LY3009104 as assessed by standard safety measures. 7 - To characterize the pharmacokinetics of LY3009104 and explore dose/PK relationships. 8 - To evaluate the impact of LY3009104 compared to placebo over the 12-week study period with regard to patient-reported outcomes.;Primary end point(s): The primary analysis will be a comparison of the combined 4 mg and 8 mg dose groups with placebo on the ACR20 response rate at 12 weeks. | — |
Countries
Hungary, United Kingdom
Outcome results
None listed